Effect of Periodontal Treatment on Stress levels in Chronic Kidney Disease Patients suffering from Periodontitis
- Conditions
- Health Condition 1: N183- Chronic kidney disease, stage 3 (moderate)
- Registration Number
- CTRI/2019/11/021944
- Lead Sponsor
- Suhani Maheshwari
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Age range: 30-60 years
Chronic Kidney Disease
Patients suffering from moderate to severe periodontitis
Non-smoking (former smokers were included if they had not smoked within 6 months of the study initiation)
No periodontal therapy within previous 6 months.
Patients who give consent
Patients with minimum 20 teeth
History of atherosclerosis involving the coronary cerebral or peripheral vascular systems
Experiencing a cardiovascular event (myocardial infarction or stroke) or undergoing coronary angioplasty or peripheral intervention procedure between the Screening Visit and randomization
Undergoing any cardiovascular surgery (valvular surgery) within 3 months of study participationPlanned revascularization or peripheral intervention procedure or other cardiovascular surgery
New York Heart Association (NYHA) Class III or IV heart failure at study participation
Patient of End stage renal disease (ESRD)/ patients on hemodialysis or peritoneal dialysis
Patients chronically treated (i.e 2 week or more) with any medication that affect periodontal status (i.e antibiotics or non-steroidal anti-inflammatory drugs) or lipid peroxidation with clinically significant or unstable organic diseases or compromised healing potential (i.e. connective tissue disorders or bone metabolic diseases).
Pregnant women or lactating.
Patients affected by active infectious diseases Asthma Diabetes Immune-compromised or taking steroid medications.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in the level of lipid peroxides-Malondialdehyde (MDA) after periodontal intervention in CKD. <br/ ><br>Renal Function will be assessed by ACR (Albumin Creatinine Ratio) <br/ ><br>Timepoint: Change in the level of lipid peroxides-Malondialdehyde (MDA) after periodontal intervention in CKD. <br/ ><br>Renal Function will be assessed by ACR (Albumin Creatinine Ratio) <br/ ><br>
- Secondary Outcome Measures
Name Time Method Clinical parameters-Probing Depth (PD) CAL (Clinical attachment Loss) Plaque index(PI) Gingival Index(GI). <br/ ><br>Change in the level of Inflammatory stress markers after periodontal intervention <br/ ><br>Timepoint: baseline 6 months and 12 months